ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury. The company's first FDA pivotal trial, called Up-LIFT, commenced in January 2021 with plans to enroll 65 subjects at up to 15 centers worldwide. ONWARD is headquartered at the High Tech Campus in Eindhoven, the EPFL Innovation Park in Lausanne, with a growing presence in Boston.
From trials to market: medtechs advance clinical programs (startupticker.ch)
New leadership for ICT and Life Sciences Swiss startups (startupticker.ch)
Swiss Medtech startups reach key development milestones (startupticker.ch)
ONWARD Medical: From Swiss Research to Life-Changing Therapies (TOP 100)
ONWARD Medical raises EUR 50.85 million to advance spinal cord injury therapies (venturelab.swiss)
Capital increase to fuel ONWARD Medical's commercialization efforts (startupticker.ch)
Industry veterans join Lifesciences and fashion-tech startups (startupticker.ch)
Two digital health companies obtain market approvals (startupticker.ch)
EPFL Trailblazers shine in Lausanne (startupticker.ch)
Key advancements in the biotech and medtech landscape (startupticker.ch)
Swiss startups transforming healthcare and societies on the winners’ podium (startupticker.ch)
Medtech startups make positive clinical progress (startupticker.ch)
Tech Tour Growth Top 50 showcases Swiss deeptech companies (startupticker.ch)
ONWARD Medical wins first commercial customers in the US (startupticker.ch)
ONWARD Medical Receives US Market Authorization for its Spinal Cord Stimulation System (startupticker.ch)
EU grants to fuel Research and development at Insphero and Onward Medical (startupticker.ch)
Swiss ingenuity shines on TIME's Best Inventions 2024 list (startupticker.ch)
ONWARD Medical secures EUR 50 million in upsized capital increase to fuel growth (venturelab.swiss)
ONWARD Medical raises EUR 50 Million in an upsized capital increase (startupticker.ch)
ONWARD Medical and partners awarded $1.1 million grant (startupticker.ch)
G-Therapeutics raises € 36 million to develop novel neuro-stimulation therapy for spinal cord injury
Brain Conference 2015
Grand Winner of Hello Tomorrow Challenge 2014
Vincent Delattre, winner of the 2014 Universal Biotech Innovation Prize
Pitch Vincent Delattre from G-Therapeutics @venture leaders kick-off event
venture leaders Interview with Vincent Delattre from G-Therapeutics